CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 92 enrolled
Drug / intervention
IMO-2055drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00729053
NCT00729053Phase 2Completed
CompareCT.gov

A Phase 2, Multi-Center, Randomized, Open-Label Study of Two Dose Levels of IMOxine® (IMO-2055 for Injection) in Patients With Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Idera Pharmaceuticals, Inc.·interventional·Posted Aug 6, 2008·Updated Jun 12, 2018

In Brief

A Phase 2 clinical trial evaluating IMO-2055 for Renal Cell Carcinoma. Completed, enrolled 92 participants across 1 site.

Detailed Summary

* Multi-Center * Randomized * Open-Label Study of single agent IMO-2055 * Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2008
Enrollment StartJun 1, 2004
Primary CompletionApr 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.9 years ago

Interventions

IMO-2055drug

immunostimulatory oligonucleotide